Evaluation of about 800 cases of influenza infection. With an estimated frequency 1480666 of severe forms requiring hospitalization of about 30 , about 130 of the 2000 women would have developed severe influenza [6], a number of cases enough to evaluate the incidence and the characteristics of A/H1N1 2009 influenza infection in pregnant women. When it appeared for epidemiological reasons (both lower attack rate and frequency of severe forms) that the objectives of the study could not be achieved, the H1N1 independent advisory board of the “Institut de Microbiologie et des Maladies Infectieuses” (IMMI) decided to stop inclusion in February 2010 after 919 inclusions. The modified endpoints were: effects of 3PO chemical information pandemic vaccination on pregnancy outcomes (gestational age at delivery, mode of delivery, mean birth weight, Apgar score, neonatal outcome) and the standard HI endpoints (seroprotection rate, geometric mean titers, seroconversion ratewith 95 confidence intervals [CI]) for immunogenicity at delivery, both for vaccinated and not vaccinated pregnant women.Figure 1. Disposition of pregnant women in the COFLUPREG cohort. doi:10.1371/journal.pone.0052303.gPandemic Influenza 2009 Vaccine and PregnancyTable 1. Participant characteristics.Characteristics Centers Center A Center B Center C Maternal age at inclusion, years 18?4 25?4 35 Body mass index, kg/m2 ,18.5 18.5?5 .25 Geographic origin Metropolitan France Overseas France Europe North Africa Sub-Saharan Africa Asia Other Single Number of children under 18 years at home 0 1 .2 Job associated with a higher risk of viral exposure Work in contact with the children Healthcare worker Professionals in contact with the public Seasonal flu vaccination in the previous 5 years Primiparous Gestational age (weeks) at inclusion ,22 [22?8] .28 doi:10.1371/journal.pone.0052303.tN ( ) Total =Three hundred and twenty (36.5 ) women were vaccinated against pandemic A/H1N1 2009 influenza between inclusion and delivery. Median gestational age at vaccination was 23.6 weeks (95 CI: 18.7?0.6) and median interval between vaccination and delivery was 92 days (95 CI: 48?34).214 (24.4) 433 (49.4) 230 (26.2)Immune Status Against Pandemic A/H1N1 2009 InfluenzaSerum samples both at inclusion and delivery were available for 678 (77.3 ) women, of whom 256 (37.8 ) had received A/H1N1 2009 influenza vaccine. At inclusion, 13 (5.1 ) of vaccinated women and 19 (4.5 ) of non-vaccinated women had HI antibodies against A/H1N1 2009 influenza strain with titers of 1:40 or greater (Table 2). At delivery, the seroprotection rate was 30.3 (95 CI: 26.8?3.9): 69.9 in vaccinated women, and 6.2 (95 CI: 4.1?.9) in non-vaccinated women. Ten (2.3 ) of the 422 women who did not receive the vaccine seroconverted between inclusion and delivery. None of them reported both fever and at least one flu symptom; one had isolated fever, two had isolated respiratory KDM5A-IN-1 web symptoms without fever, and six did not report any flu symptoms. None of them received oseltamivir. Finally, flu was laboratory-documented in 11 women among the 422 non-vaccinated women with serological data (1 with positive PCR and 10 with serological seroconversion) (rate 2.6 per 100 pregnant women [95 CI: 1.3?.6]) and no severe flu occurred.39 (4.5) 544 (62.0) 294 (33.5)67 (7.7) 639 (72.9) 170 (19.4)582 (66.3) 16 (1.8) 18325633 52 (5.9) 90 (10.3) 49 (5.6) 26 (3.0) 62 (7.1) 57 (6.5)Consequences of A/H1N1 2009 Influenza Vaccination on Pregnancy OutcomesThere was no significant difference on preg.Evaluation of about 800 cases of influenza infection. With an estimated frequency 1480666 of severe forms requiring hospitalization of about 30 , about 130 of the 2000 women would have developed severe influenza [6], a number of cases enough to evaluate the incidence and the characteristics of A/H1N1 2009 influenza infection in pregnant women. When it appeared for epidemiological reasons (both lower attack rate and frequency of severe forms) that the objectives of the study could not be achieved, the H1N1 independent advisory board of the “Institut de Microbiologie et des Maladies Infectieuses” (IMMI) decided to stop inclusion in February 2010 after 919 inclusions. The modified endpoints were: effects of pandemic vaccination on pregnancy outcomes (gestational age at delivery, mode of delivery, mean birth weight, Apgar score, neonatal outcome) and the standard HI endpoints (seroprotection rate, geometric mean titers, seroconversion ratewith 95 confidence intervals [CI]) for immunogenicity at delivery, both for vaccinated and not vaccinated pregnant women.Figure 1. Disposition of pregnant women in the COFLUPREG cohort. doi:10.1371/journal.pone.0052303.gPandemic Influenza 2009 Vaccine and PregnancyTable 1. Participant characteristics.Characteristics Centers Center A Center B Center C Maternal age at inclusion, years 18?4 25?4 35 Body mass index, kg/m2 ,18.5 18.5?5 .25 Geographic origin Metropolitan France Overseas France Europe North Africa Sub-Saharan Africa Asia Other Single Number of children under 18 years at home 0 1 .2 Job associated with a higher risk of viral exposure Work in contact with the children Healthcare worker Professionals in contact with the public Seasonal flu vaccination in the previous 5 years Primiparous Gestational age (weeks) at inclusion ,22 [22?8] .28 doi:10.1371/journal.pone.0052303.tN ( ) Total =Three hundred and twenty (36.5 ) women were vaccinated against pandemic A/H1N1 2009 influenza between inclusion and delivery. Median gestational age at vaccination was 23.6 weeks (95 CI: 18.7?0.6) and median interval between vaccination and delivery was 92 days (95 CI: 48?34).214 (24.4) 433 (49.4) 230 (26.2)Immune Status Against Pandemic A/H1N1 2009 InfluenzaSerum samples both at inclusion and delivery were available for 678 (77.3 ) women, of whom 256 (37.8 ) had received A/H1N1 2009 influenza vaccine. At inclusion, 13 (5.1 ) of vaccinated women and 19 (4.5 ) of non-vaccinated women had HI antibodies against A/H1N1 2009 influenza strain with titers of 1:40 or greater (Table 2). At delivery, the seroprotection rate was 30.3 (95 CI: 26.8?3.9): 69.9 in vaccinated women, and 6.2 (95 CI: 4.1?.9) in non-vaccinated women. Ten (2.3 ) of the 422 women who did not receive the vaccine seroconverted between inclusion and delivery. None of them reported both fever and at least one flu symptom; one had isolated fever, two had isolated respiratory symptoms without fever, and six did not report any flu symptoms. None of them received oseltamivir. Finally, flu was laboratory-documented in 11 women among the 422 non-vaccinated women with serological data (1 with positive PCR and 10 with serological seroconversion) (rate 2.6 per 100 pregnant women [95 CI: 1.3?.6]) and no severe flu occurred.39 (4.5) 544 (62.0) 294 (33.5)67 (7.7) 639 (72.9) 170 (19.4)582 (66.3) 16 (1.8) 18325633 52 (5.9) 90 (10.3) 49 (5.6) 26 (3.0) 62 (7.1) 57 (6.5)Consequences of A/H1N1 2009 Influenza Vaccination on Pregnancy OutcomesThere was no significant difference on preg.
